Macrophage Therapy for Acute Liver Injury (MAIL): a Phase 1 Randomised, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Activity of Allogeneic Alternatively Activated Macrophages in Patients with Paracetamol-induced Acute Liver Injury.

Christopher Humphries,Melisande Addison,Guruprasad Aithal,Julia Boyd,Lesley Briody,John DM Campbell,Maria Elena Candela,Ellise Clarke,James Coulson,Nicholas Downing-James,Robert John Fontana,Ailsa Geddes,Julia Grahamslaw,Alison Grant,Anna Heye,James A Hutchinson,Ashley Jones,Fiona Mitchell,Joanna Moore,Alice Riddell,Aryelly Rodriguez,Angela Thomas,Garry Tucker,Kim Walker,Christopher J Weir,Rachel Woods,Sharon Zahra,Stuart J Forbes,James Dear

DOI: https://doi.org/10.1101/2024.05.28.24306936

2024-05-28

Abstract:Introduction: Acute Liver Failure (ALF) has no effective treatment other than liver transplantation, and is commonly caused by paracetamol overdose. New treatments are needed to treat and prevent ALF. Alternatively activated macrophages (AAMs) can promote resolution of liver necrosis and stimulate hepatocyte proliferation. Using AAMs in unscheduled care requires the use of an allogeneic product. A clinical trial is needed to determine the safety and tolerability of allogeneic AAMs. Methods and analysis: A single centre, open-label, dose-escalation, phase 1 randomised trial to determine whether there is dose-limiting toxicity of AAMs in patients with paracetamol-induced acute liver injury. Randomisation will occur at higher doses. Ethics and dissemination: The trial will be conducted according to the ethical principles of the Declaration of Helsinki 2013 and has been approved by North East - York Research Ethics Committee (reference 23/NE/0019), NHS Lothian Research and Development department, and the UK Medicines and Healthcare products Regulatory Agency. When the trial concludes, results will be shared by presentation and publication. Trial registration number: .

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the lack of effective treatment methods for acute liver injury (ALI), especially acute liver injury caused by paracetamol (also known as acetaminophen) overdose. Currently, the only effective treatment for acute liver failure (ALF) is liver transplantation, but this method has problems such as high risk, high cost and scarce donors. In addition, paracetamol overdose is the most common cause of acute liver injury. In the UK, approximately 50,000 people need emergency treatment with N - acetylcysteine (NAC) every year, while in the US, the number of people seeking medical treatment due to paracetamol overdose is about 89,000 per year, and the annual treatment cost is estimated to reach 1 billion US dollars. The paper proposes a new treatment strategy, that is, using allogeneic alternatively activated macrophages (AAMs) to treat acute liver injury caused by paracetamol. Macrophage therapy can promote the resolution of liver necrosis and stimulate the proliferation of liver cells, thereby reversing or preventing the development of acute liver injury to acute liver failure. The main purpose of this study is to determine the safety and tolerance of this allogeneic AAMs, especially whether there is dose - limiting toxicity (DLT) during the dose - escalation process. In addition, the study will also explore the safety, activity and immunogenicity of AAMs. Through this study, researchers hope to find an effective, non - invasive treatment plan to reduce the need for liver transplantation in patients with acute liver injury and reduce the mortality and complication rates of related treatments.

Macrophage Therapy for Acute Liver Injury (MAIL): a Phase 1 Randomised, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Activity of Allogeneic Alternatively Activated Macrophages in Patients with Paracetamol-induced Acute Liver Injury.

Macrophage Therapy for Acute Liver Injury (MAIL): a study protocol for a phase 1 randomised, open-label, dose-escalation study to evaluate safety, tolerability and activity of allogeneic alternatively activated macrophages in patients with paracetamol-induced acute liver injury in the UK

The emerging role of alternatively activated macrophages to treat acute liver injury

Study protocol: HiSNAP trial - a multi-centre, randomised, open label, blinded end-point, safety and efficacy trial of conventional (300mg/kg) versus higher doses of acetylcysteine (450mg/kg and 600mg/kg) in patients with paracetamol overdose in the United Kingdom

Macrophages as a Cell-Based Therapy for Liver Disease

Development of an invasively monitored porcine model of acetaminophen-induced acute liver failure

Mesenchymal stem cell treatment restores liver macrophages homeostasis to alleviate mouse acute liver injury revealed by single-cell analysis.

MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure

Study protocol of a randomised, double-blind, placebo-controlled, two-arm parallel-group, multi-centre phase 3 pivotal trial to investigate the efficacy and safety of recombinant human alkaline phosphatase for treatment of patients with sepsis-associated acute kidney injury

Human umbilical cord mesenchymal stem cell transplantation for the treatment of acute-on-chronic liver failure: protocol for a multicentre random double-blind placebo-controlled trial

Alginate microencapsulated human hepatocytes for the treatment of acute liver failure in children

Acute Liver Failure and Bioartificial Liver Support

Viability testing and transplantation of marginal livers (VITTAL) using normothermic machine perfusion: study protocol for an open-label, non-randomised, prospective, single-arm trial

Macrophage activation markers are associated with infection and mortality in patients with acute liver failure

A Placebo-Controlled, Multicenter, Double-Blind, Phase 2 Randomized Trial of the Pan-Caspase Inhibitor Emricasan in Patients with Acutely Decompensated Cirrhosis

Study protocol: HepaT1ca - an observational clinical cohort study to quantify liver health in surgical candidates for liver malignancies

A clinical-scale BioArtificial Liver, developed for GMP, improved clinical parameters of liver function in porcine liver failure

Study protocol for a Randomised controlled trial of EArly transjugular intrahepatiC porTosystemic stent-shunt in Acute Variceal Bleeding (REACT-AVB trial)

A Clinical Course of Repeated Supratherapeutic Ingestion of Acetaminophen

Selonsertib, a Potential Drug for Liver Failure Therapy by Rescuing the Mitochondrial Dysfunction of Macrophage Via ASK1–JNK–DRP1 Pathway

p300/CBP inhibitor A-485 alleviates acute liver injury by regulating macrophage activation and polarization